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Abstract
Background: In human pancreatic cancer progression, the α6β1-integrin is expressed on cancer cell surface
during invasion and metastasis formation. In this study, we investigated whether interleukin (IL)-1α induces the
alterations of integrin subunits and urokinase plasminogen activator/urokinase plasminogen activator receptor
(uPA/uPAR) expression in pancreatic cancer cells. We hypothesize that the alterations of integrin subunits and
uPA/uPAR expression make an important role in signaling pathways responsible for biological behavior of
pancreatic cancer cells.
Results: IL-1α upregulated the expression of α6 and β1 integrins without any alterations of α5 and αv integrins
expression. IL-1α also induced enhancement in the expression of uPA/uPAR in pancreatic cancer cells. IL-1α
enhanced the proliferation, adhesion, and migration in pancreatic cancer cells, and IL-1α-induced alterations of
uPA/uPAR expression correlated with the increased the migration of pancreatic cancer cells. Upregulation of α6
integrin subunit and uPA/uPAR correlated with the activation of Ras and downstream extracellular signal-
regulated kinase (ERK) pathways. IL-1α-induced activation of Ras and downstream ERK can be inhibited by using
inhibitory antibodies against α6 and β1 integrin and uPAR, consistent with the inhibition of proliferation, adhesion
and migration of pancreatic cancer cells. Immunohistochemical analysis demonstrated a significant association
between strong expressions of α6 integrin with uPAR in pancreatic cancer specimens. Furthermore, the strong
expression of α6 integrin and uPAR was found to be independent prognosticator in pancreatic cancer patients.
Conclusion: Based on these findings, we conclude that IL-1α can induce selective upregulation of α6β1-integrin
and uPA/uPAR in pancreatic cancer cells and these changes may modulate the aggressive functions of pancreatic
cancer.
Background
Pancreatic cancer is one of the most aggressive common
tumors, the five-year survival rate being less than 20%
despite surgery and/or chemotherapy [1]. This very poor
prognosis is mainly due to the propensity of this tumor to
invade the adjacent structures and metastasize to distant
organs early in the course of disease. Despite intensive
efforts to improve therapy for this advanced disease, treat-
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ment remains unsatisfactory and most patients die within
months as a result of rapid local spread of the tumor or
metastatic dissemination. The biological characteristics
underlying the aggressive behavior of these tumors are
incompletely understood.
Integrins are dimeric proteins composed of noncovalently
associated α and β subunits and are divided into sub-
groups according to their preference for binding to extra-
cellular matrix (ECM) proteins or cell surface molecules
[2-4]. These adhesion molecules play principal roles in
various aspects of tumor biology. Increased expression of
laminin binding integrins or decreased expression of
fibronectin binding integrins has been correlated with
aggressive growth and metastatic capacity of several
tumors [5-8]. We previously reported that the enhance-
ment of α6β1-integrin expression by interleukin (IL)-1α
acting through IL receptor type I (IL-1RI) plays an impor-
tant role in metastatic and invasive behaviors in pancre-
atic cancer, and proved that the strong expression of the α6
integrin subunit in pancreatic cancer tissue significantly
correlated with the poor prognosis and the presence of
hepatic metastases in patients with pancreatic cancer
[9,10].
The plasminogen activation cascade is one critical path-
way frequently implicated in cancer cell growth, invasion,
and spread [10-12]. Overexpression of urokinase plas-
minogen activator (uPA) and uPA receptor (uPAR) have
been reported in human cancer tissues, and a strong cor-
relation has been associated between uPA and uPAR
expression levels and poor prognosis and uPA is localized
in primary pancreatic cancer specimens [13,14].
The activation of Ras and its downstream extracellular sig-
nal-regulated kinase/mitogen-activated protein kinase
(ERK/MAPK) pathway is one of the important roles of
integrin ligation [15]. Furthermore, overexpression of
uPAR in cancer cells is maintained by constitutively acti-
vated ERK1-dependent signaling cascade [16]. Recently it
has been demonstrated that the inhibition of the ERK/
MAPK pathway suppresses the pancreatic cancer cell inva-
sion in vitro [17] and colonic tumor growth in vivo [18].
Based on these reports, integrins in association with uPAR
may activate the Ras pathway to regulate proliferative and
invasive behaviors of cancer cells.
The aims of this study were to identify the role of integrins
and uPA/uPAR for pancreatic cancer cell adhesive and
invasive capabilities and to evaluate the correlation of
uPA and integrins expression with clinicopathological
characteristics of pancreatic cancer patients. We demon-
strated that uPA/uPAR and α6β1-integrin play important
roles in enhancement of adhesive and invasive capabili-
ties of pancreatic cancer cells through Ras/ERK signaling
pathway. Furthermore, immunohistochemical analysis
demonstrated that strong expression of uPAR and α6
integrin was found to be independent prognostic indica-
tor of pancreatic cancer patients. Our results suggest that
IL-1α induces discernibly aggressive capability in pancre-
atic cancer and that these regulations can be helpful to
understand biological processes for better translational
treatment for pancreatic cancer patients.
Results
Integrins, IL-1RI, uPA and uPAR expression and alteration 
in pancreatic cancer cells
We first analyzed three pancreatic cancer cell lines, BxPC-
3, Capan-2, and SW1990, for the presence of integrin sub-
units, IL-1RI, uPA, and uPAR. In immunoblotting analy-
sis, all three cell lines have expression of α5, α6, and αv
integrin subunits. All three cell lines lacked β4 integrin
subunits expression, while high expression of β1 integrin
Integrins, IL-1RI, and uPAR expression in pancreatic cancer  cell lines Figure 1
Integrins, IL-1RI, and uPAR expression in pancreatic cancer 
cell lines. Integrin subunits, IL-1RI, and uPAR protein expres-
sion in pancreatic cancer cell lines was determined in whole 
cell lysates by Western blotting analysis. Fifty micrograms of 
total cell lysates was separated on 10% SDS-PAGE and trans-
ferred to polyvinylidene difluoride membranes. Membranes 
were probed with antibodies against α6 integrin, αv integrin, 
β1 integrin, IL-1RI, and uPAR. β-actin Western blot served as 
a loading control.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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subunit was observed. The high expression of IL-1RI was
observed in three cell lines. The expression of uPA and
uPAR was also observed in three cell lines (Figure 1).
In flow cytometric analysis, integrin surface expression
was measured since the cells were fixed and not permea-
bilized prior to anti-integrin antibody incubation. The
expression of α5  and  αv  integrin subunits remained
unchanged in response to rIL-1α after 24 h, while the
expression of α6 and β1 integrin subunits was enhanced in
all pancreatic cancer cells (Table 1). In BxPC-3 cells, the
expression of α3  integrin subunit was enhanced in
response to IL-α, while it remained unchanged in Capan-
2 and SW1990 cell lines. The uPAR expression was also
enhanced in response to rIL-1α after 24 h in all three cell
lines. Enhancement of uPAR correlated with an increase
in the cell surface expression of uPA in pancreatic cancer
cells (Table 1).
Proliferation of pancreatic cancer cells in response to IL-
1α
We determined the proliferative response of three pancre-
atic cancer cell lines in response to rIL-1α for 24 h. Pancre-
atic cancer cells stimulated by rIL-1α showed 1.5–2.0-fold
increase in proliferation compared to untreated condi-
tions (Figure 2A and 2B). Inhibitory antibodies against α6
and β1 integrin inhibited the baseline and IL-1α-induced
proliferation of all three pancreatic cancer cell lines (Fig-
ure 2A and 2B). No effect on proliferation was observed
with control IgG (data not shown). These results indicate
that α6 and β1 integrin subunits are involved in IL-1α-
induced and normal proliferation of pancreatic cancer
cells.
Adhesion of pancreatic cancer cells in response to IL-1α
To determine whether IL-1α have any effect on the adhe-
sion of pancreatic cancer cells, we investigated the adhe-
sive response of pancreatic cancer cell lines to laminin, the
putative ligand of the α6β1-integrin, in response to rIL-1α
in pancreatic cancer cells. All three cell lines showed
enhanced adhesion when stimulated by rIL-1α for 24 h
(Figure 3). IL-1α-induced and basal adhesive response of
these cell lines was suppressed by inhibitory antibodies
against α6 and β1 integrin but not by control IgG.
Migration of pancreatic cancer cells in response to IL-1α
The migration potential of pancreatic cancer cells stimu-
lated with rIL-1α for 24 h was examined by using
Matrigel-coated invasion chambers. All three pancreatic
cancer cell lines showed significant enhancement of
migration in the presence of IL-1α. The migration of pan-
creatic cancer cells correlated with an increase in cell sur-
face bound uPA and uPAR (Table 1). IL-1α-induced
migration of pancreatic cancer cells was inhibited by anti-
α6 integrin, anti-β1 integrin, and anti-uPAR antibodies.
Especially, each antibody inhibits the basal migration of
these three cell lines (Table 2). Control IgG had no effect
on the migration of pancreatic cancer cell lines. These data
suggest that IL-1α-induced enhancement of α6 and  β1
integrin and uPAR may have a role in enhancing the
migration of pancreatic cancer cells.
IL-1α activates Ras and downstream ERK pathway in 
pancreatic cancer cells
To estimate whether IL-1α can activate Ras/ERK pathway
to regulate proliferation, adhesion and migration of pan-
creatic cancer cells, we investigated the effect of IL-1α on
this pathway. IL-1α enhanced the activation of Ras, as evi-
Table 1: Alteration of integrin subunits and uPAR in pancreatic cancer cells in response to IL-1α
Antigen IL-1α Mean fluorescence intensity
BxPC-3 Capan-2 SW1990
α3integrin - 310 ± 18 350 ± 12 411 ± 14
+3 8 3  ±  3 4 a 344 ± 18 399 ± 16
α5integrin - 40 ± 6 72 ± 9 60 ± 8
+ 44 ± 4 68 ± 8 61 ± 6
α6integrin - 520 ± 21 230 ± 11 441 ± 18
+8 3 3  ±  4 4 a 344 ± 27a 612 ± 32a
αv integrin - 77 ± 8 61 ± 9 51 ± 8
+ 71 ± 7 65 ± 9 58 ± 6
β1integrin - 997 ± 42 814 ± 31 810 ± 33
+ 1229 ± 41a 1183 ± 22a 1322 ± 24a
uPA - 34 ± 3 42 ± 2 51 ± 5
+1 4 3  ±  1 0 a 166 ± 13a 191 ± 9a
uPAR - 219 ± 17 299 ± 31 291 ± 18
+4 2 3  ±  2 6 a 588 ± 21a 524 ± 19a
IL-1α, interleukin-1α; uPA, urokinase plasminogen activator; uPAR, urokinase plasminogen activator receptor. All data are expressed as mean ± s.d. 
The p-values indicate statistical significance between data in controls and presence of IL-α. a p < 0.01.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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Effect of IL-1α on the proliferation of pancreatic cancer cell lines Figure 2
Effect of IL-1α on the proliferation of pancreatic cancer cell lines. (A) Cancer cell viability as a parameter of cell proliferation 
was assessed using the MTT assay. Three pancreatic cancer cells were treated with/without 10 ng/ml IL-1α after incubation 
with/without 0.5 µg/ml anti-α6 or anti-β1 integrin antibody for 24 h in serum free medium. Bars indicate the s.d. Experiments 
were performed in triplicate and repeated three times. **: p < 0.01, *: p < 0.05 vs. control. (B) The effect of IL-1α on cell 
growth was assessed by cell count. Three pancreatic cancer cells were treated with/without 10 ng/ml IL-1α after incubation 
with/without 0.5 µg/ml anti-α6 or anti-β1 integrin antibody for 24 h in serum free medium. Bars indicate the s.d. Experiments 
were performed in triplicate and repeated three times. **: p < 0.01, *: p < 0.05 vs. control.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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denced by the increased Ras-GTP levels in pancreatic can-
cer cells. Activation of Ras correlated with the
phosphorylation of ERK. These results indicate that IL-1α
may induce activation of ERK through a Ras-dependent
pathway (Figure 4). To evaluate whether α6β1-integrin
and uPAR affect activation of Ras and ERK, pancreatic can-
cer cells were treated for 30 min with the inhibitory anti-
bodies before being exposed to rIL-1α for 30 min.
Inhibition of α6 and β1 integrin subunits and uPAR signal-
ing pathway inhibited activation of basal/IL-1α-induced
Ras and phosphorylation of ERK (Figure 4). We per-
formed the same examinations on all three cell lines. The
results of three cell lines are very similar to the presented
findings, therefore, we presented the data of SW1990 cell
Effect of IL-1α on pancreatic cancer cell adhesion Figure 3
Effect of IL-1α on pancreatic cancer cell adhesion. Pancreatic cancer cells were cultured with 10 ng/ml IL-1α, with 10 ng/ml IL-
1α and 0.5 µg/ml anti-α6 integrin antibody, or with 0.5 µg/ml anti-β1 integrin antibody for 24 h, after which the cell adhesion 
assay was performed at 37°C for 30 min. Bars indicate the s.d. **: p < 0.01, *: p < 0.05.
Table 2: Migration of pancreatic cancer cells enhanced by IL-1α and its suppresion by anti-integrin, anti-uPAR antibodies
Pancreatic cancer cells (number of migrated cells)
BxPC-3 Capan-2 SW1990
Control 32.0 ± 6.24 (0) 27.7 ± 3.09 (0) 33.3 ± 3.09 (0)
IL-1α 59.2 ± 6.65 a (184.9) 47.0 ± 7.13 a (170.0) 63.2 ± 7.13 a (189.5)
IL-1α + IgG 58.3 ± 8.69 a (182.3) 45.8 ± 6.82 a (165.7) 62.5 ± 6.82 a (187.5)
anti-α6 integrin 21.0 ± 1.35 a (65.6) 19.9 ± 2.21 a (71.8) 23.6 ± 2.48 a (70.9)
IL-1α + anti-α6 integrin 23.0 ± 2.45 a (71.9) 22.3 ± 3.34 a (80.1) 23.3 ± 3.34 a (70.0)
anti-β1 integrin 21.1 ± 1.35 a (65.9) 23.3 ± 1.41 a (84.1) 22.1 ± 2.14 a (66.4)
IL-1α + anti-β1 integrin 23.7 ± 2.05 a (74.0) 22.5 ± 2.75 a (81.3) 23.7 ± 2.75 a (71.0)
anti-uPAR 25.2 ± 2.31 a (78.8) 20.1 ± 2.07 a (72.6) 24.1 ± 1.18 a (72.4)
IL-1α + anti-uPAR 24.5 ± 4.28 a (76.6) 21.2 ± 2.48 a (76.5) 24.8 ± 2.48 a (76.5)
IL-1α, interleukin-1α; uPAR, urokinase plasminogen activator receptor. All data are expressed as mean ± s.d. (% increase). The p-values indicate 
statistical significance between data in controls and presence of IL-α with/without respective antibodies. a p < 0.05.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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line. These results suggest that α6β1-integrin and uPAR
expression have an important role in regulating IL-1α-
induced activation of signaling pathways via IL-1RI.
Detection of total ERK 1/2 levels served as a loading con-
trol.
Immunohistochemical localization of α6 and β1 integrin 
and uPAR in ductal adenocarcinoma of pancreas
The clinical features of 42 patients with invasive ductal
adenocarcinoma of the pancreas were evaluated (Table 3).
The mean age of all patients was 64.3 ± 9.1 years (range:
45 – 81 years). None had received prior chemotherapy or
radiation therapy. Some patients received postoperative
therapy; however, there was no difference in outcome
among the various treatment modalities. The pT, pN, and
pM categories were determined according to the TNM
classification [19]. The M category was determined from
the intraoperative findings, chest and bone radiography,
ultrasonography, computed tomography, and laboratory
tests reflecting bone, chest, and liver metastasis. Ten
patients had synchronous or heterochronous liver metas-
tasis. The tissue specimens were obtained at pancreatodu-
odenectomy (n = 35) and distal pancreatectomy (n = 7).
Immunohistochemical expression of α6 and β1 integrin
subunits and uPAR was evaluated in invasive ductal aden-
ocarcinomas (n = 42) and duct cells in non-cancerous
region of pancreas (n = 42). In 20 cancerous regions, the
α6 integrin subunit and uPAR were strongly to moderately
expressed (Figure 5A and 5B), whereas the α6 integrin sub-
unit was not expressed or expressed weakly and uPAR was
absent in non-cancerous region of the pancreas (Figure 5C
and 5D). Weak-to-strong expression of the β1 integrin
subunit was observed in both malignant and non-cancer-
ous region, and there was no trend in β1 integrin subunit
expression. A significant association was found between
strong expression of α6 integrin subunit and uPAR in pan-
creatic cancer specimens (p  = 0.011, Table 3). The α6
integrin subunit expression was significantly higher in
malignant regions compared to non-cancerous regions of
the pancreas (Table 4).
There was a significant association between strong co-
expression of α6 integrin subunit with uPAR and the pres-
ence of liver metastasis (p = 0.019), lymph node metasta-
sis (p = 0.045), and retroperitoneal invasion of pancreatic
cancer (p = 0.045). No significant correlation was found
between co-expression of α6 integrin subunit with uPAR
and gender of patients, age, TNM stage, tumor location,
cancer cell differentiation, intrapancreatic nerve invasion,
lymphatic system invasion, and venous system invasion
(Table 3). We also carried out a multivariate analysis of
Effect of IL-1α on the activation of Ras and ERK pathway in SW1990 cell lines Figure 4
Effect of IL-1α on the activation of Ras and ERK pathway in SW1990 cell lines. Activation of Ras and downstream ERK was per-
formed as described in Materials and Methods. SW1990 cells were serum starved for 24 h and then treated with IL-1α in the 
presence or absence of inhibitory antibodies for 30 min. Cell lysates were prepared according to the instructions provided in 
the Ras Activation Assay Kit, and affinity precipitation of GTP-bound Ras was performed using GST-tagged Raf-RBD. Levels of 
pull-downed Ras (Ras-GTP) were determined by anti-Ras immunoblotting. Effect of IL-1α and α6, β1 integrin and uPAR inhibi-
tory antibodies on the baseline/IL-1α-induced activation of ERK was also examined by immunoblotting. Detection of total ERK 
1/2 levels served as a loading control.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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survival using the Cox's proportional hazards regression
model, including each of the pathological parameters and
strong expression of α6 integrin subunit and uPAR (Table
5). The strong expression of α6 integrin subunit (hazard
ratio = 0.547, p = 0.026) and uPAR (hazard ratio = 0.491,
p = 0.006) can be independent prognostic factors.
At the time of analysis, the median follow-up time for
patients was 17.9 months (range; 1.3 – 89.6 months) after
surgery. Twenty-six patients died of pancreatic cancer, and
three patients died of other diseases. There was a statisti-
cally significant association between cases with and with-
out strong expression of α6 integrin in poor prognosis of
patients with invasive ductal adenocarcinoma of the pan-
creas (Figure 6A). In addition, a statistically significant
association was also detected between cases with and
without strong uPAR expression (Figure 6B).
Discussion
In this study, we demonstrate that IL-1α-induced prolifer-
ation, adhesion and migration of pancreatic cancer cells
correlated with activation of Ras and downstream ERK
pathway. Inhibition of α6, β1 integrin, or uPAR signaling
pathway inhibited IL-1α-induced activation of Ras/ERK
pathway with subsequent inhibition in proliferation,
adhesion and migration of pancreatic cancer cells. These
observations suggest that α6β1-integrin and uPAR play a
significant role in IL-1α-regulated functions of pancreatic
cancer cells.
Enhancement of α6 integrin expression has been reported
previously for cells undergoing malignant transformation
such as fibroblasts [20], squamous cell carcinoma [21],
hepatocytes [22], mouse epidermal keratinocytes [23],
malignant melanoma [24], prostate cancer [25], and pan-
creatic cancer [8,9]. We previously reported that the
expression of only two subunits, the α6 and β1 integrin
subunits, by the high-metastatic cancer cell lines was
enhanced by IL-1α, and the adhesive and invasive capabil-
ity was also enhanced by IL-α[8]. In this study, we have
determined the enhancement of α6β1-integrin expression
by IL-1α and the subsequent increased migration of pan-
creatic cancer cell lines which express IL-1RI protein to
Matrigel, which contains several ECM proteins. The α6
Table 3: Comparison of α6 integrin and uPAR expression and clinicopathological findings
Strong co-expression both of α6 integrin and uPAR ap value
Yes (n = 16) No (n = 26) 0.011
Gender Male/Female 11/5 16/10 N.S.
Age (year) 64.4 ± 8.6 64.3 ± 9.5 N.S.
TNM stage I/II/III/IV 2/1/6/7 7/4/12/3 N.S.
Location H/B, T 12/4 20/6 N.S.
Liver metastasis Yes/No 7/9 3/23 0.019
Lymph node matastasis Yes/No 13/3 13/13 0.045
Cancer cell differentiation P/Muc/W/Mod 1/0/4/11 2/3/13/8 N.S.
Retroperitoneal invasion Yes/No 14/2 15/11 0.045
Intrapancreatic nerve 
invasion
Yes/No 14/2 17/9 N.S.
Lymphatic system invasion Yes/No 15/1 20/6 N.S.
Venous system invasion Yes/No 15/1 20/6 N.S.
uPAR, urokinase plasminogen activator receptor; H, head of pancreas; B, body of pancreas; T, tail of pancreas; P, papillary adenocarcinoma; Muc, 
mucinous carcinoma; W, well-differentiated adenocarcinoma; Mod, moderatery-differentiated adenocarcinoma. The pT, pN, and pM categories 
were determined according to the TNM classification [19]. The ap-values were obtained using the Mann-Whiteny U test. Values of age are given 
mean ± s.d. N.S., no significant.
Table 4: Immunohistochemical evaluation of α6 integrin and uPAR expression in pancreatic tissues
α6integrin (cases) ap uPAR (cases) ap
Group S Group W Group S Group W
cancerous region 20 22 < 0.01 25 17 < 0.01
non-cancerous 
region
53 7 04 2
uPAR, urokinase plasminogen activator receptor. The ap-values indicate statistical significance between cancerous region and non-cancerous region.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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integrin subunit is a major laminin receptor for adhesion
in laminin-rich basement membranes. In regard to the
expression of α3 integrin which binds to collagen type I,
fibronectin, and laminin with low specificity, we could
not detect any changes in Capan-2 and SW1990 cell lines,
whereas its expression was significantly enhanced in
BxPC-3 cell lines. The enhancement of α5 and αv integrins
expression was not observed in response to IL-1α in this
study. Although the relative contributions of these adhe-
sion molecules alterations appear to vary depending on
the cell line and the stimulus used, in this study we can
suggest that the α6 integrin subunit which has a strong
adhesion affinity to laminin is one of the most important
biological molecules for cancer cell adhesion and migra-
tion.
The strong expression of α6 integrin was observed in 48%
of cancerous regions of the pancreas, while the α6 integrin
subunit was weakly expressed in non-cancerous regions (p
< 0.01). Interestingly, in non-cancerous regions of pancre-
atic tissues, α6 integrin subunit was not or only weakly
expressed. The α6 integrin subunit is an integral part of
Expression of α6 integrin subunit and uPAR in specimens from pancreatic cancer patients Figure 5
Expression of α6 integrin subunit and uPAR in specimens from pancreatic cancer patients. Tissue samples fixed in 10% formalin 
and embedded in paraffin were stained using the labeled streptavidin biotin method and specific antibodies as described in 
Materials and Methods. (A) Strong expression of the α6 integrin subunit in a specimen from ductal adenocarcinoma of pan-
creas. Magnification: ×200. (B) Strong expression of the uPAR in a specimen from ductal adenocarcinoma of pancreas. Magnifi-
cation: ×200. (C) Weak expression of the α6 integrin subunit in a specimen from non-cancerous region of pancreas. 
Magnification: ×200. (D) The expression of uPAR was absent in a specimen from non-cancerous region of pancreas. Magnifica-
tion: ×200.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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hemidesmosomes. It is possible that the detachment of
cancer cells from the pancreatic tissues and resultant
metastasis formation in the target organs may be easier
where α6 integrin subunit expression in non-cancerous
regions of pancreatic tissues is weak or not observed. And
the enhanced expression of the α6 integrin subunit via IL-
1 signaling transmitted through IL-1RI may results in
increased invasive and metastatic capabilities of cancer
cells in cancerous tissues. In addition, the induction of
microenvironment induced expression of adhesion and
metastasis-related molecules may serve to regulate the
process of pancreatic cancer proliferation, adhesion and
invasion.
In this study, no expression of β4 integrin subunit was
observed in three pancreatic cancer cell lines studied. The
lack of β4 integrin subunit is consistent with the reported
for prostate cancer. The progression of the cancer from
intraepithelial neoplasia to invasive prostate carcinoma
results in loss of β4 integrin expression and is replaced by
alternative α6β1-integrin functions [26]. Concerning the β
integrin subunit, pancreatic cancer cells that express β1
integrin with naturally acquired high constitutive activity
were able to maintain the necessary balance of adhesion
and release by means of coordinated activation and inac-
tivation of integrin affinity [27].
In this study, we have focused in identifying some of the
molecules that are regulated by IL-1α with a view to gain
better understanding of the IL-1α induced molecular
mechanisms that may contribute to the progression and
dissemination of pancreatic cancer. We previously
reported that blocking IL-1RI with neutralizing antibody
inhibited the adhesion and migration of pancreatic cancer
cells. We also proved that IL-1α had no demonstrable
effect on pancreatic cancer cell lines without expressing IL-
1RI [8]. We herein demonstrated that the proliferation of
pancreatic cancer cells was enhanced by exposing to IL-
1α. IL-1α also enhanced the adhesion and migration of
pancreatic cancer cell lines expressing the IL-1RI, and
these enhancements correlated with the enhancement of
α6β1-integrin and uPA/uPAR expression. Based on our
results, enhancement of α6β1-integrin and uPA/uPAR
expression in pancreatic cancer cells occurs in the presence
of IL-1RI.
The concomitant overexpression of uPA and uPAR was
found to be associated with shorter survival in pancreatic
cancer patients [13]. On the other hand, Harvey et al.
reported that there were not any correlation with the co-
expression of uPA and uPAR [28]. In our immunohisto-
chemical analysis, uPAR was strongly expressed in 59.5%
of cancerous regions of pancreatic cancer, whilst the
expression of uPAR was absent in non-cancerous region of
the pancreas. A significant association was demonstrated
between strong expression of α6  integrin subunit and
uPAR in pancreatic cancer specimens. The strong co-
expression of α6 integrin subunit with uPAR supports our
results in vitro and suggests that α6β1-integrin and uPAR
play a significant role in aggressive functions of pancreatic
cancer cells. In this study, we demonstrated a significant
correlation between co-expression of α6 integrin subunit
with uPAR and the presence of liver metastasis, lymph
node metastasis, and the retroperitoneal invasion in
patients with pancreatic ductal adenocarcinoma. We also
found that the strong expression of α6 integrin subunit
and uPAR correlated with the patient's poor prognosis.
Furthermore, multivariate analysis demonstrated that the
strong expression of α6 integrin subunit and uPAR can be
independent prognostic indicators in patients with pan-
creatic ductal adenocarcinoma. These observations sug-
gest that the diagnostic evaluation of α6 integrin subunit
and uPAR expression might provide valuable prognostic
information to aid treatment strategies for pancreatic can-
cer patients.
Recent reports demonstrated that integrins directly associ-
ate with uPAR to mediate cellular function [29-32]. uPAR
has been reported to associate with many signaling mole-
cules and to mediate signal transduction [33]. The α6
integrin/uPAR interaction has been demonstrated in
human ovarian cancer cell [32] and prostate cancer cell
lines [34], and these data suggest that signaling through
α6 integrin and uPAR may be essential for ensuring cancer
Table 5: Multiple analysis on prognosis of patients with pancreatic cancer
Hazard Ratio 95% confidence interval ap
Cancer cell differentiation 1.417 0.669 – 3.526 0.105
Retroperitoneal invasion 1.025 0.528 – 1.853 0.938
Intrapancreatic nerve invasion 1.604 0.605 – 1.890 0.164
Lymphatic system invasion 1.570 0.702 – 3.476 0.253
Venous system invasion 0.534 0.325 – 1.308 0.079
Lymph node metastasis 0.907 0.404 – 1.207 0.717
Strong expression of α6 integrin 0.547 0.295 – 0.782 0.026
Strong expression of uPAR 0.491 0.276 – 0.819 0.006
Statistical significance was indicated by ap < 0.05.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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phenotype expression. Recently, Ahmed et al. reported the
loss of uPA/uPAR-mediated ERK activation with downreg-
ulation of uPAR expression in colon cancer cells [35].
They also reported that the upregulation of α6 integrin
and uPA/uPAR correlated with the activation of Ras and
its downstream ERK pathway in ovarian cancer cells [32].
uPA/uPAR interaction with β1 integrin has been shown to
activate ERK pathway [36] and disruption oft his interac-
tion can result in loss of adhesion and tumor progression
in nude mice [37]. Furthermore, it has been reported that
integrin-ECM interactions activate ERK 1/2 signaling cas-
cades [37]. We demonstrated that IL-1α stimulation and
cancer cell adhesion to collagen type IV enhanced the
focal adhesion kinase (FAK) protein association with β1
integrin and FAK phosphorylation. And these enhance-
ments correlated with the activation of Ras/ERK signaling
pathways in pancreatic cancer cells [38]. The integrin-
uPAR interaction is very important as many integrin
receptors activate intracellular signal pathways to fully
activate cell survival and proliferation pathways [39].
Conclusion
In summary, upregulation of α6 integrin subunit and uPA/
uPAR correlated with the activation of Ras and down-
stream ERK pathways. IL-1α-induced activation of Ras
and downstream ERK pathway can be inhibited by using
inhibitory antibodies against α6 and β1 integrin and uPAR,
consistent with the inhibition of proliferation, adhesion
and migration of pancreatic cancer cells. Immunohisto-
chemical analysis demonstrated a significant association
between strong co-expression of α6 integrin and uPAR in
pancreatic cancerous regions, and the strong expression of
α6 integrin and uPAR was found to be independent prog-
nostic indicators in pancreatic cancer patients. Based on
these results, IL-1α induces discernibly aggressive capabil-
ity in pancreatic cancer and these regulations can be help-
ful to understand biological processes of pancreatic
cancer.
Methods
Cell culture
The human pancreatic cancer cell lines, BxPC-3, Capan-2,
and SW1990, were from the American Type Culture Col-
lection (Rockville, MD). The BxPC-3 cells were main-
tained in RPMI 1640 (Gibco BRL, Eggenstein, Germany)
supplemented with 10% fetal calf serum (FCS). SW1990
and Capan-2 cells were maintained in Dulbecco modified
Eagle medium (Gibco BRL) with high glucose and 10%
FCS. All cells were incubated at 37°C in a humidified
atmosphere of 5% CO2 in air.
Tissues
Human pancreatic tissues were obtained in Department
of Gastroenterological Surgery, Nagoya City University
Hospital with patients' or their relatives' informed con-
sent. Tissue samples were fixed in 10% formalin and then
embedded in paraffin. Immunohistochemical studies on
tumor-free pancreatic tissue were performed using non-
cancerous regions of tumor-containing pancreas.
Reagents
Recombinant human IL-1α (rIL-1α) was provided by
Gibco BRL. The monoclonal antibodies (mAbs) used
included anti-β1 (P5D2), anti-α6 (GoH3), anti-αv (AV1),
and anti-β4 (439-9B) from Chemicon International, Inc.
(Temecula, CA, USA); anti-IL-1RI (35730) from Gen-
zyme/Techne; anti-uPA-specific antibody (#3471) and
uPAR specific antibody (#3936) from American Diagnos-
tica (Temecula, CA, USA); anti-phospho-ERK 1/2 (Thr
202/Tyr 204), anti-ERK 1 (C-16), and anti-ERK 2 (C-14)
from Santa Cruz Biotechnology (Santa Cruz, CA, USA).
Western blot analysis
The cells were lysed in lysis buffer (50 mM Tris-HCl, pH
7.5, 150 mM NaCl, 1 mM CaCl2, 1% Triton X-100, 0.1%
SDS, 0.1% Nonidet P-40, 2 mM PMSF, 1 mM vanadate, 5
Kaplan-Meier survival curves for pancreatic cancer patients Figure 6
Kaplan-Meier survival curves for pancreatic cancer patients. 
(A) A comparison of survival curves between cases with 
(thick line) and without (broken line) strong expression of α6 
integrin. (B) A comparison of survival curves between cases 
with (thick line) and without (broken line) strong expression 
of uPAR.BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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µg/ml Trasylol, 10 µM Pepstatin A and 10 µM leupeptin).
Following a low-speed spin (500 rpm, 5 min) to pellet
nuclei and cell debris, the supernatant fraction was further
centrifuged (100,000 g, 30 min), and the crude plasma
membranes obtained in the pellet were re-suspended in
20 mM Tris-HCl (pH 7.4). Protein concentrations were
determined with a BCA protein assay kit (Pierce, Rock-
ford, IL, USA). The amounts of samples were 50 µg per
each lane. Western blot analyses were performed follow-
ing SDS-PAGE. The lysates were separated by 10% SDS-
polyacrylamide gel electrophoresis, transferred to polyvi-
nylidene difluoride membranes (Immobilon PVDF;
Nihon Millipore Ltd., Tokyo, Japan) and immunoblotted
with each antibody.
Flow cytometric analyses
Flow-cytometric analysis was performed using FACScan
(Becton Dickinson Immunocytometry Systems, Moun-
tain View, CA, USA). The indirect immunofluorescence
method was applied to stain the cancer cells with various
monoclonal antibodies as the primary antibody (stained
for 30 min at room temperature), followed by the addi-
tion of the secondary antibody conjugated fluorescein iso-
thiocyanate (Dako, Glostrup, Denmark). Results are
expressed as mean fluorescence intensity for triplicate
determinations.
Cell proliferation assay
Pancreatic cancer cell proliferation was determined using
the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide dye reduction method] assay and cell
count. In MTT assay, pancreatic cancer cells were seeded at
a density of 2 × 103 cells/100 µl into 96-well plates and
allowed to adhere overnight. Culture media were
replaced, and the cells then cultured in medium alone
(control) or in medium with/without 10 ng/ml of rIL-1α.
After 24 h of incubation, cells were cultured for 4 h with
the metabolic substrate tetrazolium salt MTT at a final
concentration of 0.5 mg/ml. Formazan was detected spec-
torphotometically at 540 nm with a multiwell spectro-
photometer (ELISA Reader; Biotek Instruments,
Burlington, VT, USA).
In cell count, pancreatic cancer cells were seeded at a den-
sity of 2 × 105 cells on 35 mm well in media containing
10% FCS. After 24 h, cells were starved with 0.5% FCS for
another 24 hours. Culture media was replaced to the fresh
serum free media, and added rIL-1α at concentration of
10 ng/ml. After 24 h incubation, cells were washed once
with phosphate-buffered saline (PBS), trypsinized, and
centrifuged for 3 min at 1,500 rpm. The cell pellet was re-
suspended in 2 ml of PBS and cells were counted using a
light microscope.
Before the stimulating experiments with IL-1α were
attempted, the lowest effective concentration was deter-
mined using rIL-1α at concentrations of 0.1 ng/ml, 0.5
ng/ml, 1.0 ng/ml, 10 ng/ml, and 100 ng/ml. A concentra-
tion of 10 ng/ml was determined to be the lowest effective
concentration for stimulating experiments (data not
shown). In some experiments, 0.5 µg/ml anti-α6 integrin
or anti-β1 integrin mAbs was added to the cancer cells for
24 h. Before the blocking experiments were attempted, the
lowest effective antibody concentration was determined
using antibodies at concentrations of 0.1 µg/ml, 0.25 µg/
ml, 0.5 µg/ml, 0.75 µg/ml, and 1.0 µg/ml. A concentra-
tion of 0.5 µg/ml was determined to be the lowest effec-
tive concentration for blocking experiments (data not
shown). Experiments were performed in triplicate and
repeated three times.
Adhesion assay
Adhesion assay was performed as described previously
with some modifications [8]. 24-well plates coated with
laminin, the putative ligand of the α6β1-integrin, were
obtained from Becton-Dickinson Labware (Franklin
Lakes, NJ, USA). Briefly, cancer cells were incubated for 24
hours with/without rIL-1α (10 ng/ml) and then added (2
× 105 cells/well) to each well and incubated at 37°C for 30
min. The wells were then washed three times with PBS to
remove unattached cells. In some experiments, 0.5 µg/ml
anti-α6 or anti-β1 integrin antibodies were added to the
cancer cells for >30 min prior to addition of rIL-1α.
Migration assay
The migration response of pancreatic cancer cells in
response to IL-1α was determined by using Matrigel-
coated invasion chambers (Becton and Dickinson, USA).
Cancer cells were added (1 × 105 cells/well) to the inner
chamber of a cell culture insert and incubated at 37°C for
24 h, either with culture media containing 10 ng/ml rIL-
1α or with culture media containing 10 ng/ml rIL-1α and
0.5 µg/ml anti-α6 integrin, anti-β1 integrin, or anti-uPAR
antibodies. Complete medium containing 20% fetal
bovine serum served as a chemo-attractant in the lower
chamber. To quantitate migration, the filters were fixed in
70 % ethanol for 30 min and stained with Giemsa. Cells
were removed from the upper surface of the filters by rub-
bing gently with a cotton-tipped applicator. Cells that had
migrated through the membrane were counted in five ran-
dom microscope fields of the lower filter surface.
Ras activation assay
The activation state of Ras was determined using the Ras
Activation Assay Kit provided by Upstate (Lake Placid, NY,
USA). Briefly, pancreatic cancer cells were serum starved
for 24 h, and then incubated in serum-free medium with/
without rIL-1α (10 ng/ml) for 30 min. Cells were har-
vested and lysed in lysis buffer (100 mM HEPES, pH 7.5,BMC Cell Biology 2006, 7:8 http://www.biomedcentral.com/1471-2121/7/8
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200 mM NaCl, 1% Nonidet P-40, 10 mM MgCl2, 5 mM
EDTA and 10% glycerol), and supernatant prepared by
centrifugation for 5 min at 4°C at 14,000 g. Ras-GTP from
various treated lysates was "pulled down" using the GST
fusion protein corresponding to human Ras binding
domain of Raf-1 bound to agarose. The presence of Ras-
GTP was detected by Western blotting using anti-Ras anti-
body (Upstate).
Immunohistochemistry
Pancreatic tissues were studied using the labeled streptavi-
din biotin method [40,41]. Specimens were sectioned at
3.5-µm thick and deparaffinized. After rinsing in phos-
phate-buffered saline (pH 7.2), 10% bovine serum
(Wako, Osaka, Japan) was applied for 10 min to block
nonspecific binding. Sections were then incubated with
anti-α6 integrin (overnight at 4°C), anti-β1 integrin (over
night at 4°C), or anti-uPAR (60 min at 37°C) mAbs as pri-
mary antibodies. After rinsing in phosphate-buffered
saline, sections were treated with biotinylated anti-mouse
immunoglobulin (Ig) (Dako, Copenhagen, Denmark) for
10 min. After rinsing in phosphate-buffered saline, sec-
tions were treated with horseradish peroxidase-labeled
streptavidin (Dako, Copenhagen, Denmark) for 10 min-
utes. The peroxidase reaction was visualized by incubating
the sections with 0.02 % 3,3'-diaminobenzidine tetrahy-
drochloride in 0.05 M Tris buffer (pH 7.6) with 0.01 %
hydrogen peroxide, followed by hematoxylin counter-
staining. Negative control sections were prepared using
normal mouse IgG instead of primary antibody.
Immunohistochemical evaluation
Two observers (H.S. and H.F.) independently evaluated
the immunostaining results. The concordance ratio was >
90%. Differences of opinion were resolved by reaching a
consensus with the assistance of a third evaluator (Y.M.).
The intensity of tissue staining was graded semiquantita-
tively on a 4-point scale (-, +, ++, and +++). Likewise, the
proportion of cells stained was assessed on a 4-point scale
(1, 0–15%; 2, 15–50%; 3, 50–85%; 4, 85–100% cells
stained). To evaluate immunohistochemical findings
from pancreatic cancer tissues, cases were classed in
strongly staining (Group S) and weakly staining groups
(Group W) by intensity and proportion of immunostain-
ing. Immunostaining of intensity more than +++ or a
staining area was more than 3 for α6 integrin subunit, β1
integrin subunit, or uPAR was defined as Group S.
Statistical analysis
Statistical comparisons were made using the Student's t
test for paired observations or by one-way ANOVA for
multiple comparisons. The Mann-Whitney U  test was
used to compare the immunohistochemical characteris-
tics. Differences between Kaplan-Meier survival curves
based on Immunohistochemical analysis were tested with
the Wilcoxon test. Multiple survival analysis was calcu-
lated according to Cox's proportional hazards model. Sta-
tistical significance was indicated by p < 0.05. Data are
presented as mean ± standard deviations (s.d.). Each
experiment was repeated three times and was carried out
in triplicate.
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